Cartesian Therapeutics, Inc. (RNAC) Cash Flow Statement

This decoupling appears to be driven almost entirely by non-operating items — likely revaluation of equity stakes or warrant adjustments — rather than any change in core operations. The fact that operating cash flow stayed in a relatively tight -$7M to -$23M range while net income swung by over $100M across adjacent quarters suggests reported earnings bear little signal about actual cash generation. For an analyst, this means any EPS-based valuation would be misleading; the operating cash flow line is the only credible read on real economic performance.

The quarterly burn rate has remained stubbornly elevated at roughly -$15M to -$24M in eight of the last ten periods, with no visible narrowing trend even as capex remained negligible. This suggests the burn is almost entirely driven by opex — principally R&D — rather than any capital investment program. Without a revenue base to offset it, investors should monitor whether management has disclosed the remaining cash runway, as the trajectory implies continued heavy capital consumption absent a financing event or partnership inflection.

These swings, particularly the 2024Q3 inflow that temporarily produced positive free cash flow, likely reflect lumpy milestone payments or deferred revenue recognition rather than any structural improvement in the cash cycle. With zero recurring revenue as of 2026Q2, traditional working capital efficiency metrics are essentially inapplicable; the movements more likely reflect episodic contractual cash receipts. This pattern warrants further investigation because it means any single-quarter cash flow improvement should not be extrapolated into a trend.

The divergence here is unusual for a pre-commercial biotech: typically net income is less negative than operating cash flow when non-cash charges inflate losses, but the magnitude — especially the -$92.6M and -$56.8M quarters with comparatively modest OCF negatives — implies extraordinary items well beyond standard D&A or SBC. Based on Cartesian's reported statements, this may indicate impairment or revaluation charges that reduce book earnings without consuming cash, which is a less destructive form of loss but still signals significant capital allocation risk in prior periods.